SCYNEXIS (SCYX) Insider Ann Hanham Buys 2,875 Shares

Ann Hanham Acquires Stake in SCYNEXIS, Inc.

Ann Hanham acquired 2,875 shares of SCYNEXIS, Inc. (NasdaqCM: SCYX) on June 26, 2026. This transaction forms part of a notable round of insider activity at the Jersey City-based biotechnology firm. The scale of the purchase stands out for a company of this size, matching identical acquisitions made across the leadership team on the exact same day.

Coordinated Insider Activity Across Leadership

Ann Hanham was far from the only insider stepping up to pick up shares during this window. On June 26, 2026, Guy Macdonald acquired 2,875 shares, while David Hastings also picked up 2,875 shares. Tinmouth Brian Philippe added 2,875 shares to his holdings on that date as well. Armando Anido completed the group by picking up an identical block of 2,875 shares. These coordinated purchases brought multiple key figures into alignment as they each added the exact same number of shares to their personal holdings on a single day.

Stock Price Trades Near Yearly Lows

Shares of SCYNEXIS changed hands at $4.07 as the broader market evaluated the recent activity. The biotechnology equity has experienced a wide trading band over the past year, reaching a 52-week high of $9.12 while sitting not far above its 52-week low of $3.53. With a market capitalization of $43.8 million, the company navigates a volatile valuation environment typical for clinical-stage specialty drug developers.

Analysts Set New Price Targets

Wall Street firms continue to monitor the clinical progress and financial trajectory of the company. On August 13, 2026, Guggenheim maintained its Buy rating on the stock while lifting its price target from $24.00 to $33.00. Across the wider analyst community, sentiment is captured by three opinions holding a mean target price of $36.55, with estimates stretching from a low of $32.00 to a high of $44.64.

Focused Biotechnology Operations

SCYNEXIS, Inc. is a specialty drug developer focused on creating treatments and preventive options for difficult-to-treat and drug-resistant fungal infections. The company commercializes BREXAFEMME for vulvovaginal candidiasis and advances early-stage assets like the SCY-247 compound through clinical trials. This operational focus underpins the capital requirements and market expectations facing the firm as it moves through its development pipeline.

What to Watch Next for SCYX

Investors looking for the next financial updates from the firm will focus on November 4, 2026, when the company is scheduled to release its next earnings report. Observers will also track subsequent regulatory filings to monitor any further insider transactions or shifts in institutional ownership as clinical trials progress through the rest of the year.